nefopam has been researched along with Seizures in 4 studies
Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26)
nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.
5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Furthermore, we tested nefopam for protection against both, maximal electroshock-induced seizures (MES), and isoniazid-induced seizures in mice." | 3.74 | Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. ( Desogus, CM; Fernández-Sánchez, MT; Ferrero-Gutiérrez, A; Groppetti, A; Manfredi, B; Novelli, A; Pérez-Gómez, A; Rossoni, G, 2007) |
| "Nefopam is a centrally acting non-opioid analgesic with a mechanism of action that is not completely understood." | 1.37 | Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice. ( Cięszczyk, J; Czuczwar, K; Czuczwar, M; Kiś, J; Saran, T; Turski, WA; Łuszczki, JJ, 2011) |
| "Nefopam can cause unpleasant adverse effects and there are important cautions and contraindications with this analgesic." | 1.29 | Adverse reactions associated with nefopam. ( Pillans, PI; Woods, DJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czuczwar, M | 1 |
| Czuczwar, K | 1 |
| Cięszczyk, J | 1 |
| Kiś, J | 1 |
| Saran, T | 1 |
| Łuszczki, JJ | 1 |
| Turski, WA | 1 |
| Novelli, A | 1 |
| Groppetti, A | 1 |
| Rossoni, G | 1 |
| Manfredi, B | 1 |
| Ferrero-Gutiérrez, A | 1 |
| Pérez-Gómez, A | 1 |
| Desogus, CM | 1 |
| Fernández-Sánchez, MT | 1 |
| Durrieu, G | 1 |
| Olivier, P | 1 |
| Bagheri, H | 1 |
| Montastruc, JL | 1 |
| Pillans, PI | 1 |
| Woods, DJ | 1 |
4 other studies available for nefopam and Seizures
| Article | Year |
|---|---|
Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice.
Topics: Analgesics, Non-Narcotic; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Synergism | 2011 |
Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation.
Topics: Analgesics, Non-Narcotic; Animals; Anticonvulsants; Antitubercular Agents; Calcium Channels, L-Type; | 2007 |
Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Analgesics, Non | 2007 |
Adverse reactions associated with nefopam.
Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Angina Pectoris; Female; Humans; Male; Middle Age | 1995 |